Introduction {#j_bjmg-2016-0036_s_001}
============

The most common cause of solid pelvic tumors and an indication for gynecological surgery in women are uterine leiomyomas (ULM), also known as uterine fibroids. Approximately 20.0-40.0% of women during their reproductive period have ULM \[[@j_bjmg-2016-0036_ref_001]\]. These are benign fibrous tumors descendent from a single uterine smooth muscle cell \[2\]. Clinical problems associated with ULM are excessive bleeding and secondary anemia, increased urinary frequency, pelvic discomfort, bladder and bowel dysfunction, a sensation of pressure in the lower abdomen and pain during intercourse \[[@j_bjmg-2016-0036_ref_003]\]. During the reproductive period of women, infertility and recurrent spontaneous abortions, fetal anomalies and fetal malpresentation have also been associated with leiomyomas \[[@j_bjmg-2016-0036_ref_004]\].

Despite their high prevalence, the etiopathogenesis of the ULM remains unclear. Several predisposing factors, including race, heredity, reproductive factors and lifestyle have been linked to ULM \[[@j_bjmg-2016-0036_ref_005]\]. Furthermore, ULM is a complex disease, which means that interactions between multiple genes, hormones, growth factors, interleukins (ILs), and environment are involved in the tumorigenesis of ULM \[[@j_bjmg-2016-0036_ref_006]\].

Some molecules, including ILs and their receptors, may influence tumor biology, tumor immunology and immuno-surveillance by mediating abnormal cell-cell signaling in the tumor micro-environment \[[@j_bjmg-2016-0036_ref_007]\]. Several studies suggest that ILs and other cytokines are involved in the development of a variety of neoplasms such as glioma \[[@j_bjmg-2016-0036_ref_008]\], gastric cancer \[[@j_bjmg-2016-0036_ref_009]\] and gynecological neoplasms \[[@j_bjmg-2016-0036_ref_010]\]. Moreover, elevated levels of ILs have been found in the uterine cavity of patients with ULM \[[@j_bjmg-2016-0036_ref_011]\].

Interleukin-related single nucleotide polymorphisms (SNPs) might affect IL production and influence the course of the illness, as well as both disease resistance and susceptibility \[[@j_bjmg-2016-0036_ref_012]\]. Thus, certain risk alleles may indicate an individual's degree of genetic predisposition to disease risk. Previous studies have investigated the association between *IL1B, IL1Ra, IL2, IL4, IL8, IL12, IL18 and IL12RB1* gene polymorphisms and the occurrence of ULM \[13-16\]. Some of these studies reported a significant association between *IL4, IL1B* and *IL12RB1* and ULM development \[13-15\]. In addition, clinical and genetic differences have been noted between subtypes of solitary and multiple ULM \[[@j_bjmg-2016-0036_ref_017], [@j_bjmg-2016-0036_ref_018]\]. In this study, however, we focused on cytokines derived from τ helper type 2 (Th2) cells (IL-4, IL-12 and IL-13), hypothesizing that they might be good candidates as they are involved in the avoidance of tumor immuno-surveillance at the molecular level. The IL-23 and IL-12 are closely associated with Th17-helper phenotype and play a role in suppressing tumor immune response \[[@j_bjmg-2016-0036_ref_019]\]. Furthermore, some functional studies showed effect of SNPs in *IL4* and *IL4R* genes on their expression, particularly SNP in the *IL4* gene correlates with enhanced IL-4 activity \[[@j_bjmg-2016-0036_ref_020]\] and SNP in the *IL4R* gene functionally impacts the signaling and upregulating of the receptor's response to IL-4, which in turn results in activation of the STAT6 pathway \[[@j_bjmg-2016-0036_ref_021]\]. Recently, clinical and genetic differences were noted between subtypes of solitary and multiple ULM \[[@j_bjmg-2016-0036_ref_017], [@j_bjmg-2016-0036_ref_018]\]. The aim of our study was to further evaluate polymorphisms in genes coding for ILs, specifically SNPs with a known functional role in IL expression, including *IL4* and *IL4R*, SNPs with previously contradictory results in different populations, including *IL12RB1*, as well as SNPs previously not yet analyzed for ULM, including *IL12B, IL23R* and *IL13*. In addition, we also investigated possible genetic differences between solitary and multiple subtypes of ULM.

Materials and Methods {#j_bjmg-2016-0036_s_002}
=====================

Study Subjects {#j_bjmg-2016-0036_s_002_001}
--------------

In this study, we recruited 181 ULM patients and 41 women without ULM as a control group at the Department of General Gynecology and Gynecological Urology (University Medical Centre Maribor, Maribor, Slovenia) as described previously \[[@j_bjmg-2016-0036_ref_017]\]. Additionally, 92 subjects were included to represent the general population. Uterine leiomyomas patients were divided into two subgroups: 85 were patients with solitary ULM and 96 were patients with multiple ULM, with a mean age at diagnosis of 46 ± 11 years. Controls were also divided into two subgroups. The first group (healthy control) consisted of 41 women without ULM but diagnosed with pelvic organ prolapse as described previously \[[@j_bjmg-2016-0036_ref_017]\], with a mean age of 60+11 years, and the second group (normal population) consisted of 92 healthy individuals, with a mean age of 43 + 12 years. Demographic and clinical parameters of ULM patients analyzed in this study have been described previously \[[@j_bjmg-2016-0036_ref_017]\]. Additionally, quantitative measurements of the 17ß-estradiol levels in serum were performed using ARCHITECT i2000SR Immunoassay Analyzer (Abbott Laboratories, Abbott Park, IL, USA) according to the manufacturer's instructions. The study protocol was approved by the Slovenian National Committee for Medical Ethics and the Institutional Review Board (KME 43/10/15).

Selection and Genotyping of *IL4* (rs2070874), *IL4R*(rs1801275), *IL12B* (rs6887695), *IL12RB1* (rs11575934) and *IL23R* (rs7517847) Single Nucleotide Polymorphisms {#j_bjmg-2016-0036_s_002_002}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

The rs2070874 (*IL4)* and rs1801275 (*IL4R)* SNPs were selected according to their known functional role in IL expression. Single nucleotide polymorphisms rs11575934 (*IL12RBI)*, rs6887695 (*IL12B)*, rs20541 (*IL13)* and rs7517847 (*IL23R)* were previously reported to be associated with other ULM-related immune-mediated diseases, such as inflammatory bowel disease \[[@j_bjmg-2016-0036_ref_022]\], glioblastoma \[[@j_bjmg-2016-0036_ref_023]\], cervical adenocarcinoma and an increased risk of tuberculosis \[[@j_bjmg-2016-0036_ref_024]\].

Genotyping *of IL4* (rs2070874), *IL4R* (rs1801275), *IL12B* (rs6887695, located \~60 kb upstream of the *IL12B* coding region), *IL12RB1* (rs11575934) and *IL23R* (rs7517847) SNPs was performed by polymerase chain reaction (PCR) followed by the restriction fragment length polymorphism (RFLP) technique. The PCR primers and restriction enzymes were selected using the GeneRunner program (Hastings Software Inc., Hastings, NY, USA). A total of 50 ng of genomic DNA was mixed with oligonucleotide primers in a final volume of 10 μL containing 2 mM MgC12, 0.2 mM dNTP mix, 10 mM Tris-HCl and 0.25 U Taqpolymerase (Fermentas, Waltham, MA, USA). The PCR conditions, primer sequences and the concentration of each primer are shown in [Table 1](#j_bjmg-2016-0036_tab_001){ref-type="table"}. Polymerase chain reaction amplification was performed in a Professional Standard PCR Thermocycler (TProfessional Basic; Biometra GmbH, Göttingen, Germany). The PCR products were digested with a restriction enzyme at 37 °C overnight. The PCR products were electrophoresed on a 2.0% agarose gel stained with ethidium bromide, and visualized on an ultraviolet transilluminator. Restriction enzymes and fragment sizes after digestion are listed in [Table 1](#j_bjmg-2016-0036_tab_001){ref-type="table"}.

###### 

Primer sequences, primer concentrations, annealing temperatures and size of polymerase chain reaction product; restriction enzyme, enzyme concentration and size of DNA fragments after restriction for *IL12B* (rs6887695). *IL12RB1* (rs11575934), *1L23R* (rs7517847), *1L4* (rs2070874) and *1L4R* (rs1801275).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP ID (gene)   Primer Sequence (5'-3')       Final Concentration of Primer (nM)   Ta (°C)   PCR Product Size (bp)   Restriction Enzyme   Enzyme Concentration (units)   Allele   DNA Fragment Size After Restriction (bp)
  --------------- ----------------------------- ------------------------------------ --------- ----------------------- -------------------- ------------------------------ -------- ------------------------------------------
  rs6887695\      F-TTTCAGCGTGAGACCATTCA\       250                                  55        245                     *Hph*I               0.5                            C\       207+38\
  (*IL12B*)       R-CCCCTAGGTCACAAGCGTAG                                                                                                                                   G        161+46+38

  rs11575934\     F-GGACAATTCTTACGGCCTGA\       250                                  55        203                     *Pvu*II              0.5                            A\       104+99\
  (*IL12RB1*)     R-TCTAATGCTTGCCCCTGTTC                                                                                                                                   G        203

  rs7517847\      F-TCTGCCAATTCCCTAAAC\         375                                  52        259                     *Hpy*F3I             0.25                           G\       259\
  (*IL23R*)       R-AAGTAGGTGTGGATTGCC                                                                                                                                     T        168+91

  rs2070874\      F-TAGAGATATCTTTGTCAGCATT\     250                                  52        188                     *Mn*II               0.1                            C\       64+30\
  (*IL4*)         R-AGACCCATTAATAGGTGTCG                                                                                                                                   T        94

  rs1801275\      F-TCTCGGCCCCCACCAGTGGCGATC\   125                                  60        418                     *Pvu*I               0.2                            A\       209\
  (*IL4R*)        R-GAGGTCTTGGAAAGGCTTATAC                                                                                                                                 G        186+23
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SNP ID: single nucleotide polymorphism identity; Ta: annealing temperature; PCR: polymerase chain reaction; bp: base pair; F: forward; R: reverse.

Genotyping of the *IL13* (rs20541) Single Nucleotide Polymorphism {#j_bjmg-2016-0036_s_002_003}
-----------------------------------------------------------------

Genotyping of the *IL1 3* (rs20541) SNP was performed by high resolution melting (HRM) curve analysis following touchdown PCR amplification. Primers were designed using Primer3 (<http://simgene.com/Primer3>), and manufactured by Sigma-Aldrich Produktions GmbH, Steinheim, Germany. Primer sequences were as follows: forward 5'-CTG CAA ATA ATG ATG CTT TCG-3' and reverse 5'-ACC TGC TCT TAC ATT TAA AGA AAC TT-3'. The touchdown PCR amplification was performed on a LightCycler®480 detection system (Roche Applied Science, Mannheim, Germany). Samples were amplified in reactions containing 2 μL. DNA (2.5 ng/μL), 3 μL, of 2X LightCycler® 480 High Resolution Melting Master Mix (Roche Applied Science), 200 nM of each primer, 0.8 μL of MgCl~2~ (2 mM final concentration) and RNase-free water in a final reaction volume of 10 μL. The touchdown PCR program was as follows: initial denaturation at 95 °C for 10 min., followed by 45 cycles of 10 seconds at 95 °C, 15 seconds at 65 °C (secondary target temperature 53 °C, with 0.5 °C/step) and 10 seconds at 72 °C. The HRM curve analysis was performed with temperature ranges used for the melting curve generation from 65 °C to 95 °C with 25 signal acquisitions per °C.

Statistical Analysis {#j_bjmg-2016-0036_s_002_004}
--------------------

All statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS), version 23 (IBM Corporation, Armonk, NY, USA). Genetic polymorphisms were expressed as bivariate descriptive parameters, either by each of the two SNP alleles or by either of two genetic models assuming a dominant/recessive influence of the non-ancestral allele on a particular phenotype. Appropriate statistical techniques and methods were used, depending on properties of the measured parameter. Association analyses were done by either the two-sided Fisher's exact test, risk determination, Mann-Whitney test or Independent Samples *t*-test. Predictive models for bivariate variables describing phenotype groups were constructed using logistic regression with a stepwise exclusion of parameters (backward: Wald exclusion method with parameter exclusion criteria *at p* \>0.05). Initially included parameters were: all SNPs, adenomyosis, age at diagnosis, family predisposition, menarche, number of pregnancies, parity, body mass index, intake of oral contraceptives, intake of gestagenes, age at first sexual intercourse, and smoking. We did not perform a Bonferroni correction in our statistical analysis to avoid an unnecessary increase of type II errors \[[@j_bjmg-2016-0036_ref_025]\]. Power of statistical association analysis (*p)* for dominant and recessive genetic models was calculated using G\*Power computer software (Heinrich Heine University, Dusseldorf, Germany). The power of the study was calculated post hoc, using the generally accepted standard error rate α *=* 0.05.

Results {#j_bjmg-2016-0036_s_003}
=======

Association Analysis of Selected Single Nucleotide Polymorphisms {#j_bjmg-2016-0036_s_003_001}
----------------------------------------------------------------

We found statistically significant differences between the SNP rs 20541 of gene *IL13* and ULM patients. The genotyping of *IL13* and other genes was performed by HRM or RFLP analyses, as described in Materials and Methods and shown in [Figure 1](#j_bjmg-2016-0036_fig_001){ref-type="fig"}. The frequency of the TT genotype of rs20541 was higher in the group of healthy controls (8.7%) compared to all patients with ULM (1.0%) (*p =* 0.018, OR = 0.184, 95% CI = 0.048-0.712) using the recessive genotype model (TT *vs*. CT+CC). We also found a higher frequency of the TT genotype of rs20541 in all controls (6.8%) compared to patients with multiple ULM, for which the frequency of the TT genotype was 1.0% using the recessive genotype model (TT *vs*. CT+CC) (*p =* 0.048, OR = 0.145, 95% CI = 0.018-1.165). The association was also statistically significant when comparing multiple ULM, where the frequency of the TT genotype was (1.0%) and healthy individuals from the normal population, where the frequency of the TT genotype was (8.7%) (*p =* 0.017, OR = 0.111, 95% CI = 0.014-0.902) using the recessive genotype model (TT *vs*. CT+ CC). Power of association analysis between phenotype (ULM *vs*. all controls) and dominant (CC *vs*. CT+TT) or recessive (CC+CT *vs*. TT) genetic models of rs20541 was *p =* 0.381 and *p* = 0.940, respectively. For other tested SNPs, there were no significant differences in genotype or allele frequencies between patients and controls. Results of association analyses for rs20541 of the *IL13* gene are shown in [Tables 2](#j_bjmg-2016-0036_tab_002){ref-type="table"} and [3](#j_bjmg-2016-0036_tab_003){ref-type="table"}.

![Primer sequences, primer concentrations, annealing temperatures and size of polymerase chain reaction product; restriction enzyme, enzyme concentration and size of DNA fragments after restriction for *IL12B* (rs6887695), *IL12RB1* (rs11575934), *IL23R* (rs7517847), *IL4* (rs2070874) and *IL4R* (rs1801275).](j_bjmg-2016-0036_fig_001){#j_bjmg-2016-0036_fig_001}

###### 

Association analysis for *IL13* (rs20541) in women with uterine leiomyomas and controls.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNPID\     Genotype   ULM *n*=181 (%)   Norma\] Population *n*=96 (%)   Healthy Controls *n*=41 (%)   All Controls *n*=133 (%)   Statistical Analyses   ULM *vs*. All Controls   ULM *vs*. Healthy Controls   ULM *vs*. Normal Population                               
  (gene)                                                                                                                                                                                                                                                                  
  ---------- ---------- ----------------- ------------------------------- ----------------------------- -------------------------- ---------------------- ------------------------ ---------------------------- ----------------------------- ------------- ------------- -------------
                                                                                                                                                          CC *vs*.\                TT *vs*.\                    CC *vs*.\                     TT *vs*.\     CC *vs*.\     TT *vs*.\
                                                                                                                                                          CT+TT                    CT+CC                        CT+TT                         CT+CC         CT+TT         CT+CC

  rs20451\   CC\        101(58.0)\        48 (52.2)\                      23 (52.2)\                    71 (53.4)\                 *p* value\             0.42\                    0.588\                       0.862\                        0.574\        0.367\        **0.018**\
  (*IL13*)   CT\        70 (40.2)\        36(39.1)\                       17(39.1)\                     53(39.8)\                  OR\                    1.208\                   2.5\                         0.083\                        0.702\        1.268\        0.184\
             TT         3(1.7)            8(8.7)                          1(8.7)                        9(6.8)                     95% CI                 0.767-1.904              0.222-28.096                 0.545-2.151                   3.071-6.924   0.763-2.108   0.048-0.712
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SNP ID: single nucleotide polymorphism identity; ULM: uterine leiomyomas; OR: odds ratio; 95% CI: 95% confidence interval.

###### 

Association analysis for *IL13* (rs20541) in women with multiple uterine leiomyomas and controls.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP ID\    Genotype   Solitary\    Multiple\    Healthy\     All Controls\   Statistical\   Multiple ULM *vs*.\   Multiple ULM *vs*.\   Multiple ULM vs.\                               
  (gene)                ULM\         ULM\         Controls\    *n*=133 (%)     Analyses       All Controls          Healthy Controls      Normal Population                               
                        n=85 (%)     *n*=96 (%)   *n*=41 (%)                                                                                                                              
  ---------- ---------- ------------ ------------ ------------ --------------- -------------- --------------------- --------------------- ------------------- ------------- ------------- -------------
                                                                                              CC *vs*.\             TT *vs*.\             CC *vs*.\           TT *vs*.\     CC *vs*.\     TT *vs*.\
                                                                                              CT+TT                 CT+CC                 CT+TT               CT+CC         CT+TT         CT+CC

  rs20451\   CC\        42(53.8)\    59(61.5)\    34 (52.2)\   71 (53.4)\      *p* value\     0.280\                **0.048**\            0.573\              0.511\        0.573\        **0.017**\
  (*IL13*)   CT\        34 (43.6)\   36 (37.5)\   17(39.1)\    53 (39.8)\      OR\            1.392\                0.145\                1.248\              0.421\        1.248\        0.111\
             TT         2 (2.6)      1(1.0)       1(8.7)       9(6.8)          95% CI         0.816-2.375           0.018-1.165           0.595-2.619         0.026-6.899   0.595-2.619   0.014-0.905
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SNP ID: single nucleotide polymorphism identity; ULM: uterine leiomyomas; OR: odds ratio; 95% CI: 95% confidence interval.

Association Between Evaluated Single Nucleotide Polymorphisms and Clinical Characteristics {#j_bjmg-2016-0036_s_003_002}
------------------------------------------------------------------------------------------

When we compared selected SNPs with clinical characteristics of patients within a particular phenotype groups, differences were found between solitary and multiple ULM. In solitary ULM, rs1801275 (*IL4R)* was associated with the age at first sexual intercourse (*p =* 0.004) where median age at first intercourse of patients exhibiting the GG genotype was 19 years and the age of patients exhibiting either the AA or AG genotype was 18. In multiple ULM, rs1801275 (*IL4R)* was associated with the age at diagnosis (*p =* 0.003) where patients with the GG genotype were younger at diagnosis (27.5 years) compared to patients with the AA or AG genotype (45 years).

The SNP rs6887695 (*IL12B)* was associated with parity for solitary and multiple ULM subtypes. In solitary ULM, an association was found using the C *vs*. G allele model (*p =* 0.029) and using the CC *vs*. CG+GG genetic model (*p =* 0.016). On average, patients with the C allele or CC genotypes had a parity of one and patients with the G allele or the CG or GG genotypes had a parity of two. In multiple ULM, an association was detected for the C *vs*. G allele model (*p =* 0.049) and for the CC *vs*. CG+GG genetic model (*p =* 0.048). On average, patients with the C allele or CC genotype had a parity of two, and patients with the G allele or CG or GG genotypes had a parity of one. In multiple ULM, rs20541 (*IL13)* was associated with 17ß-estradiol serum levels in the follicular phase of the menstrual cycle (*p =* 0.003) where patients with the CC genotype had a higher 17ß-estradiol levels (0.525 nmol/L) compared to patients with either the CT or TT genotypes (0.130 nmol/L).

In addition, rs11575934 (*IL12RB1)* was also associated with parity in multiple ULM. An association was found for the A *vs*. G allele model (*p =* 0.004) and in AA *vs*. AG+ GG genetic model (*p =* 0.009). On average, patients with the A allele and AA genotypes had a parity of two, and patients with the G allele or AG or GG genotypes had a parity of one.

Logistic Regression Analyses {#j_bjmg-2016-0036_s_003_003}
----------------------------

To further investigate possible parameters that are associated with increased risk of ULM development, we performed logistic regression analyses of selected genetic and clinical parameters in relation to solitary and multiple ULM occurrence ([Table 4](#j_bjmg-2016-0036_tab_004){ref-type="table"}). For SNP rs1801275 (*IL4R)*, association was found in allele and genotype genetic model with the ULM phenotype subgroups, where carrying the G allele (OR = 3.641, *ρ =* 2.19 χ 10-2) or genotypes AG or GG (OR = 6.975, ρ = 7.49x 10-3), presence of adenomyosis (OR = 11.315, *ρ =* 4.55 χ 10-3), higher age at diagnosis (OR = 1.086, *p* = 3.24 χ 10-2), positive family history (OR = 0.152, *p* = 3.03 χ 10-3), earlier menarche (OR = 0.401, *ρ =* 2.10 χ 10-4), lower number of pregnancies (OR = 0.559, *p* = 1.99 χ 10-2) and lower age at first sexual intercourse (OR = 0.655, *ρ =* 1.81 χ 10-2), all increase the risk of multiple ULM development.

###### 

Logistic regression for the prediction of uterine leiomyomas subgroups. \[Dependent variable: ULM subtype (multiple *vs*. solitary).\]

  Independent Variables                             Exp (B)    95% CI for Exp (B)   Coefficient *ρ* Value   Nag. R^2^       Accuracy (%)   
  ------------------------------------------------- ---------- -------------------- ----------------------- --------------- -------------- ------
                                                               **Lower**            **Upper**                                              
  rs1801275 (*IL4R)* (G *vs*. Aalleles)             3.641      1.206                10.996                  2.19 × 10^-2^                  
  Adenomyosis (present *vs*. absent)                7.967      2.668                23.790                  2.01 × 10^-4^                  
  Age at diagnosis (years)                          1.093      1.036                1.153                   1.17 × 10^-3^                  
  Family predisposition (negative *vs*. positive)   0.200      0.087                0.462                   1.62 × 10^4^                   
  Menarche (year)                                   0.445      0.323                0.613                   7.41 × 10^-7^   0.485          75.0
  Number of pregnancies                             0.562      0.405                0.781                   5.84 × 10^-4^                  
  Age at first sexual intercourse (year)            0.674      0.533                0.852                   9.59×10^-4^                    
  Constant                                          7831870                                                 1.40×10^-6^                    
  rs1801275 (*IL4R)* (AG+GG *vs*. AAgenotypes)      6.975      1.680                28.958                  7.49 × 10^-3^                  
  Adenomyosis (present *vs*. absent)                11.315     2.118                60.454                  4.55 × 10^-3^                  
  Age at diagnosis (years)                          1.086      1.007                1.171                   3.24 × 10^-2^                  
  Family predisposition (negative *vs*. positive)   0.152      0.044                0.528                   3.03 × 10^-3^                  
  Menarche (year)                                   0.401      0.247                0.650                   2.10×10^-4^     0.535          76.6
  Number of pregnancies                             0.559      0.343                0.912                   1.99 × 10^-2^                  
  Age at first sexual intercourse (year)            0.655      0.462                0.930                   1.81 × 10^-2^                  
  Constant                                          55741666                                                3.98×10^-4^                    

Exp (B): odds ratio, as given by logistic regression in SPSS; 95% CI: 95% confidence interval.

Discussion {#j_bjmg-2016-0036_s_004}
==========

In the present case-control study, we investigated the associations among six SNPs in selected candidate cytokine genes and the risk of ULM in the Slovenian population. Results of our study suggest that an association of ULM with rs20541 (*IL13)* exists, but for the other analyzed candidate SNPs in selected genes, we could not confirm association with ULM development in Slovenian women. Our study showed that SNP rs20541 in the *IL13* gene is associated with a significantly decreased risk of ULM development. The presence of the TT genotype of *IL13* rs20541 SNP may have aprotective role against ULM development in Slovenian women. So far, an association between rs20541 (*IL13)* and some tumors such as renal cell carcinoma \[[@j_bjmg-2016-0036_ref_026]\], bladder cancer \[[@j_bjmg-2016-0036_ref_027]\] and glioblastoma \[[@j_bjmg-2016-0036_ref_023]\] has been reported, but no study to date reports the relationship between rs20541 (*IL13)* and the presence of ULM. Chu *et al*. \[[@j_bjmg-2016-0036_ref_026]\] showed the same protective effect of the rs20541 (*IL13)* TT genotype for renal cell carcinoma development in a Chinese population. The SNP rs20541 (*IL13)* is a functional polymorphism located in exon 4, conferring a change in the amino acid sequence from arginine (Arg) to glutamine (Gln) at codon 130 and it could influence the transcriptional expression of IL-13 \[[@j_bjmg-2016-0036_ref_026]\]. Graves *et al*. \[[@j_bjmg-2016-0036_ref_028]\] demonstrated that the rs20541 (*IL13)* A allele (Gln) compromises IgE production and elevated serum IgE levels in 1399 children from three different populations. Several epidemiological studies suggest an inverse association between IgE levels and the risk of glioma \[[@j_bjmg-2016-0036_ref_029], [@j_bjmg-2016-0036_ref_030]\], non-Hodgkin lymphoma \[[@j_bjmg-2016-0036_ref_030]\] and pancreatic cancer \[[@j_bjmg-2016-0036_ref_031]\]; however, to date, there are no epidemiological studies available on the relationship between IgE levels and ULM. The *IL13* gene encodes IL-13, a pleiotropic Th2 cytokine secreted by many cell types, but especially activated T-cells. Interleukin-13 plays a critical role in many aspects of allergic reaction onset by inducing IgE synthesis \[[@j_bjmg-2016-0036_ref_032]\]. A gene expression study detected over-expression of *IL13* in ULM compared with myometrial tissue \[[@j_bjmg-2016-0036_ref_033]\], which increased the expression of tumor necrosis factor-α (TNF-α), one of the leiomyoma growth factors \[[@j_bjmg-2016-0036_ref_034]\]. The *IL13* gene also caused overexpression and release of matrix metallo-proteinases required for promoting cell proliferation and invasion of tumors \[[@j_bjmg-2016-0036_ref_035]\]. In some tumors, IL-13 inhibits tumor immuno-surveillance by acting as a tumor cell growth factor \[[@j_bjmg-2016-0036_ref_036]\]. Terabe *et al*. \[[@j_bjmg-2016-0036_ref_037]\] demonstrated that IL-13 is necessary for down-regulation of tumor immuno-surveillance in a tumor model through the IL-4R-STAT 6 pathway. Furthermore, natural killer τ (NKτ) cells in response to tumor growth, could produce IL-13 and induce myeloid cells to secrete transforming growth factor-ß (TGF-ß) that inhibits tumor immuno-surveillance in several mouse tumor models \[[@j_bjmg-2016-0036_ref_038]\]. Most published association studies in ULM so far used as a control group general population. However, as there are many women in the general population with undetected ULM, estimated to be around 9.0% \[[@j_bjmg-2016-0036_ref_039]\], it is important to include as many women as possible with proven absence of ULM in the control group, as we did in our study. It should be acknowledged that the limitation of the study was the relatively low number of participants because high prevalence of the disease would call for a large sample size. Nonetheless, the strength of the present study was a precise selection of participants with regard to the presence of ULM.

In our study, we also analyzed SNPs in other *IL* genes, *IL4, IL4R, IL12RB1, IL12B* and *IL23R*. However, no statistically significant associations has been found between different genotypes and ULM. The IL-13 and IL-4 have similar immunoregulatory functions and share a common IL-4R chain on their receptors \[[@j_bjmg-2016-0036_ref_040]\].They play a critical role in the down-regulation of anti-tumor immunity \[[@j_bjmg-2016-0036_ref_040]\]. Both, or at least one copy of the τ allele in the rs2070874 (*IL4)* polymorphism is associated with higher IL-4 serum levels \[[@j_bjmg-2016-0036_ref_020]\]. The study by Sosna *et al*. \[[@j_bjmg-2016-0036_ref_014]\] tested the same rs2070874 (*IL4)* polymorphism and they observed an association with the risk for ULM.

An association between rs1801275 (*IL4R)* and a lower age at first sexual intercourse in solitary ULM, and between rs1801275 (*IL4R)* and age at diagnosis in the group of patients with multiple ULM has been found. Likewise, a recent genome-wide association study of 125,667 UK Biobank participants identified 38 loci associated with age at first sexual intercourse with several of these loci having associations with other reproductive and behavioral traits, such as age at first birth, number of children, irritable temperament and risk-taking propensity \[[@j_bjmg-2016-0036_ref_041]\]. Our observations could be explained by the fact that a lower age at first sexual intercourse presents a higher risk of contracting sexually transmitted diseases (STD). Another possibility is that hormonal factors associated with perimenopause and/or the culmination after 20-30 years of stimulation by sex hormones could predispose individuals toward ULM occurrence \[[@j_bjmg-2016-0036_ref_006]\].

For the first time, we provide evidence that rs1801275 (*IL4R)* is a possible contributor to different age at diagnosis of patients with multiple ULM. Our data suggest that carriers of the AA or AG genotypes may exhibit both a later onset of the disease and a higher risk for developing multiple ULM. Additionally, logistic regression confirmed a codependent association of rs1801275 in *IL4R*, adenomyosis, positive family history and an earlier menarche in patients with multiple ULM. Some in *vitro* data suggest a common pathogenetic mechanisms in adenomyosis and ULM \[[@j_bjmg-2016-0036_ref_042]\]. Another well-known risk factor associated with ULM is familial predisposition, which increases the risk of ULM in female relatives of women with ULM \[[@j_bjmg-2016-0036_ref_043]\]. Early onset of menarche increases the overall number of myometrium cell divisions resulting in an increased chance of mutation within some genes expressed in the myometrium \[[@j_bjmg-2016-0036_ref_044]\]. In our study, we showed that in multiple ULM patients, CT and TT genotypes of rs20541 (*IL13)* additionally predispose patients to lower E2 levels compared to the CC genotype. The 17ß-estradiol (E2) is an established stimulator of ULM growth through binding to the α and β estrogen receptors subtypes (ER) and upregulates the gene expression of multiple growth factors \[[@j_bjmg-2016-0036_ref_045]\]. Shao *et al*. \[[@j_bjmg-2016-0036_ref_018]\] demonstrated that 17ß-estradiol concentrations were lower in multiple ULM compared to solitary ULM.

In conclusion, our study suggests that the polymorphism rs20541 in the *IL13* gene may be associated with a decreased risk for ULM development. Additionally, SNP rs1801275 in the *IL4R* gene predisposes the risk for solitary ULM in patients with a lower age at first sexual intercourse and a risk for multiple ULM in patients with earlier onset of disease. Further research on a larger sample size in ethnically diverse populations, including a subsequent functional evaluation, is warranted. Currently, there are not enough data on ULM in association to the selected genes to perform meta-analysis. However, when more association studies of these candidate SNPs have been accumulated in the future, the meta-analysis will be possible and our study is an important step toward this goal.
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